Postprandial Hyperlipidemia: Association with Inflammation and Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis

• Published in: Biomedicines Vol. 10; no. 1; p. 133
• Main Authors: Mena-Vázquez, Natalia, Redondo-Rodríguez, Rocío, Rioja, José, Jimenez-Nuñez, Francisco Gabriel, Manrique-Arija, Sara, Lisbona-Montañez, Jose Manuel, Cano-García, Laura, Rojas-Gimenez, Marta, Ureña, Inmaculada, Valdivielso, Pedro, Fernández-Nebro, Antonio
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 08.01.2022; MDPI
• Subjects: apolipoprotein B48; Apolipoproteins; Arteriosclerosis; Atherosclerosis; Body mass index; C-reactive protein; Cholesterol; Cytokines; Diabetes; Disease; Dyslipidemia; Enzymes; Fasting; Fatty acids; High density lipoprotein; Hyperlipidemia; Inflammation; Laboratories; Lipids; Lipoproteins; Multivariate analysis; Physical activity; postprandial lipemia; Questionnaires; Rheumatoid arthritis; subclinical atherosclerosis; Triglycerides; Tumor necrosis factor-α; Ultrasonic imaging; Variables; Spain; apolipoprotein B48; triglycerides; inflammation; rheumatoid arthritis; subclinical atherosclerosis; postprandial lipemia
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines10010133

To describe postprandial lipidemia in patients with rheumatoid arthritis (RA) and to analyze its association with subclinical atherosclerosis and inflammatory activity. Observational study of 80 cases of RA and 80 sex- and age-matched controls. We excluded individuals with dyslipidemia. Postprandial hyperlipidemia (PPHL) was defined as postprandial triglycerides >220 mg/dL and/or postprandial ApoB48 levels >75th percentile (>p75). Plasma lipids, cholesterol, triglycerides, ApoB48, and total ApoB were evaluated at baseline and after a meal. Other variables analyzed included subclinical atherosclerosis (defined as presence of carotid atheromatous plaque), inflammatory activity (disease activity score (DAS28-ESR)), cytokines, apolipoproteins, and physical activity. A multivariate analysis was performed to identify factors associated with PPHL in patients with RA. A total of 75 patients with RA and 67 healthy controls fulfilled the inclusion criteria. PPHL was more frequent in patients with RA than controls (No. (%), 29 (38.70) vs. 15 (22.40); = 0.036), as was subclinical atherosclerosis (No. (%), 22 (30.10) vs. 10 (14.90); = 0.032). PPHL in patients with RA was associated with subclinical atherosclerosis (OR (95% CI) 4.69 (1.09-12.11); = 0.037), TNF-α (OR (95% CI) 2.00 (1.00-3.98); = 0.048), high-sensitivity C-reactive protein (OR (95% CI) 1.10 (1.01-1.19); = 0.027), and baseline triglycerides (OR (95% CI) 1.02 (1.00-1.04); = 0.049). PPHL was more frequent in patients with RA than in controls. PPHL in patients with RA was associated with inflammation and subclinical atherosclerosis.